Article Text

PDF
Original article
Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer
  1. Lucía Pérez-Carbonell1,
  2. Clara Ruiz-Ponte2,
  3. Carla Guarinos1,
  4. Cristina Alenda1,3,
  5. Artemio Payá1,3,
  6. Alejandro Brea1,2,
  7. Cecilia M Egoavil3,4,
  8. Adela Castillejo4,
  9. Victor M Barberá4,
  10. Xavier Bessa5,
  11. Rosa M Xicola6,
  12. María Rodríguez-Soler1,7,
  13. Cristina Sánchez-Fortún7,
  14. Nuria Acame7,
  15. Sergi Castellví-Bel8,
  16. Virgínia Piñol8,
  17. Francesc Balaguer8,
  18. Luis Bujanda9,
  19. María-Luisa De-Castro10,
  20. Xavier Llor6,
  21. Montserrat Andreu5,
  22. Angel Carracedo2,
  23. José-Luis Soto4,
  24. Antoni Castells8,
  25. Rodrigo Jover1,7
  1. 1Unidad de Investigación, Hospital General Universitario, Alicante, Spain
  2. 2Galician Public Foundation of Genomic Medicine (FPGMX), CIBERER, Genomics Medicine Group, Hospital Clínico, Santiago de Compostela, University of Santiago de Compostela, Galicia, Spain
  3. 3Department of Pathology, Hospital General Universitario, Alicante, Spain
  4. 4Molecular Genetics Department, Hospital General Universitario, Elche, Spain
  5. 5Gastroenterology Department, Hospital del Mar, Barcelona, Spain
  6. 6Department of Medicine and Cancer Center, University of Illinois, Chicago, Illinois, USA
  7. 7Unidad de Gastroenterología, Hospital General Universitario, Alicante, Spain
  8. 8Department of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
  9. 9Hospital Donostia, Universidad del País Vasco, CIBERehd, San Sebastián, Spain
  10. 10Gastroenterology Department, Complexo Hospitalario de Vigo, Vigo, Spain
  1. Correspondence to Dr Rodrigo Jover, Unidad de Gastroenterología, Hospital General Universitario de Alicante, Pintor Baeza 12, 03010 Alicante, Spain; jover_rod{at}gva.es

Abstract

Background The selection of patients for genetic testing to rule out Lynch syndrome is currently based on fulfilment of at least one of the revised Bethesda criteria followed by mismatch repair (MMR) status analysis. A study was undertaken to compare the present approach with universal MMR study-based strategies to detect Lynch syndrome in a large series of patients with colorectal cancer (CRC).

Methods 2093 patients with CRC from the EPICOLON I and II cohorts were included. Immunohistochemistry for MMR proteins and/or microsatellite instability (MSI) analysis was performed in tumour tissue. Germline MLH1 and MSH2 mutation analysis was performed in patients whose tumours showed loss of MLH1 or MSH2 staining, respectively. MSH6 genetic testing was done in patients whose tumours showed lack of MSH6 expression or a combined lack of MSH2 and MSH6 expression but did not have MSH2 mutations. PMS2 genetic testing was performed in patients showing isolated loss of PMS2 expression. In patients with MSI tumours and normal or not available MMR protein expression, all four MMR genes were studied.

Results A total of 180 patients (8.6%) showed loss of expression of some of the MMR proteins and/or MSI. Four hundred and eighty-six patients (23.2%) met some of the revised Bethesda criteria. Of the 14 (0.7%) patients who had a MMR gene mutation, 12 fulfilled at least one of the revised Bethesda criteria and two (14.3%) did not.

Conclusions Routine molecular screening of patients with CRC for Lynch syndrome using immunohistochemistry or MSI has better sensitivity for detecting mutation carriers than the Bethesda guidelines.

  • Cancer genetics
  • polyposis
  • colorectal neoplasia
  • colorectal carcinoma
  • colorectal cancer genes
  • colorectal cancer
  • cancer
  • cancer prevention
  • cancer epidemiology
  • colon carcinogenesis
  • colonic neoplasms
  • cancer susceptibility
  • cancer syndromes
  • gastrointestinal cancer
  • endoscopy
  • DNA microsatellite instability
  • methylation

Statistics from Altmetric.com

Footnotes

  • Funding The present work was supported by grants from Instituto de Salud Carlos III (INT09/208 and PI08/0726) to RJ, from Fundación de la CV para la Investigación en el Hospital General Universitario de Alicante to RJ, LPC, AP and CA, grant SAF 07-64873 from the Ministerio de Educación y Ciencia to AC, grants from the Asociación Española contra el Cáncer (Fundación Científica and Junta de Barcelona) to AC, funds from the AGAUR (2009 SGR 849) to AC. LP-C is a recipient of a predoctoral grant from Instituto de Salud Carlos III (FI07/00303). CIBERehd is funded by the Instituto de Salud Carlos III. CG is a recipient of a predoctoral grant from Conselleria d'Educació de la Generalitat Valenciana (VALi+d). SC-B is supported by a contract (CP 03-0070) from Instituto de Salud Carlos III.

  • Competing interests NA is a research nurse granted by MSD. None of the other authors have any potential conflicts to disclose.

  • Ethics approval Ethics approval was provided by CEIC HGU Alicante.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.